Ra Pharmaceuticals Reports Positive Data

Ra Pharmaceuticals Inc. said data demonstrated that treatment of Escherichia coli sepsis with its lead candidate RA101295 was associated with significant organ protection and markedly reduced mortality.

Researchers evaluated the effect of RA101295 in baboons receiving lethal doses of E. coli. Compared with placebo, treatment with RA101295 blocked sepsis-induced inflammation, preserved endothelial cell function, decreased leukocyte activation, and reduced overall mortality, while exhibiting no detrimental effects on the clearance of bacteria. “These data indicate that C5 inhibition could play an important role in the treatment of bacterial sepsis and other acute systemic inflammatory conditions,” said Doug Treco, CEO of Ra Pharmaceuticals.